{"id":"https://openalex.org/W2012503689","doi":"https://doi.org/10.1111/1755-5922.12093","title":"A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK 9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects","display_name":"A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK 9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects","alternate_titles":[],"publication_year":2014,"publication_date":"2014-11-24","ids":{"openalex":"https://openalex.org/W2012503689","doi":"https://doi.org/10.1111/1755-5922.12093","mag":"2012503689","pmid":"https://pubmed.ncbi.nlm.nih.gov/25256660","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4262094"},"language":"en","primary_location":{"id":"doi:10.1111/1755-5922.12093","doi":"https://doi.org/10.1111/1755-5922.12093","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1755-5922.12093","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1755-5922.12093","source":{"id":"https://openalex.org/S73613154","display_name":"Cardiovascular Therapeutics","issn_l":"1755-5914","issn":["1755-5914","1755-5922"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2012503689"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1755-5922.12093","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082422797","display_name":"Catherine Lunven","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Catherine Lunven","raw_affiliation_strings":["Sanofi Paris France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi Paris France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044569334","display_name":"Tobias Paehler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138838","display_name":"Sanofi (Germany)","ror":"https://ror.org/03ytdtb31","country_code":"DE","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210138838"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tobias Paehler","raw_affiliation_strings":["Sanofi Frankfurt Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi Frankfurt Germany","institution_ids":["https://openalex.org/I4210138838"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044299629","display_name":"Franck Poitiers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Franck Poitiers","raw_affiliation_strings":["Sanofi Paris France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi Paris France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017264414","display_name":"Aur\u00e9lie Brunet","orcid":"https://orcid.org/0000-0002-5541-2083","observed_orcids":["https://orcid.org/0000-0002-5541-2083"]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Aur\u00e9lie Brunet","raw_affiliation_strings":["Sanofi Montpellier France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi Montpellier France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106342721","display_name":"Jacques Rey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jacques Rey","raw_affiliation_strings":["Sanofi Paris France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi Paris France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108225270","display_name":"Corinne Hanotin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Corinne Hanotin","raw_affiliation_strings":["Sanofi Paris France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi Paris France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108012827","display_name":"William J. Sasiela","orcid":"https://orcid.org/0009-0004-2281-3384","observed_orcids":["https://orcid.org/0009-0004-2281-3384"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"William J. Sasiela","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA","institution_ids":["https://openalex.org/I186523950"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5082422797"],"corresponding_institution_ids":["https://openalex.org/I3018075036"],"apc_list":{"value":2160,"currency":"USD","value_usd":2160},"apc_paid":{"value":2160,"currency":"USD","value_usd":2160},"fwci":4.709,"has_fulltext":true,"cited_by_count":62,"citation_normalized_percentile":{"value":0.95593635,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"32","issue":"6","first_page":"297","last_page":"301"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9502000212669373,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9502000212669373,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.005499999970197678,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14126","display_name":"Intramuscular injections and effects","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alirocumab","display_name":"alirocumab","score":1.0},{"id":"https://openalex.org/keywords/pcsk9-inhibitors","display_name":"PCSK9 inhibitors","score":0.828000009059906},{"id":"https://openalex.org/keywords/subcutaneous-injection-site","display_name":"subcutaneous injection site","score":0.8510000109672546},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8149999976158142},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9929999709129333},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.8410000205039978},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7540000081062317},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.5899999737739563}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9492499232292175},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7407919764518738},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6867573261260986},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6139051914215088},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5003347396850586},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3781468868255615},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.18744680285453796}],"mesh":[{"descriptor_ui":"D000071449","descriptor_name":"Proprotein Convertase 9","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012697","descriptor_name":"Serine Endopeptidases","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D043484","descriptor_name":"Proprotein Convertases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D043484","descriptor_name":"Proprotein Convertases","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/1755-5922.12093","doi":"https://doi.org/10.1111/1755-5922.12093","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1755-5922.12093","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1755-5922.12093","source":{"id":"https://openalex.org/S73613154","display_name":"Cardiovascular Therapeutics","issn_l":"1755-5914","issn":["1755-5914","1755-5922"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Therapeutics","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4262094","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4262094/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovasc Ther","raw_type":"Text"},{"id":"pmid:25256660","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25256660","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular therapeutics","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1111/1755-5922.12093","doi":"https://doi.org/10.1111/1755-5922.12093","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1755-5922.12093","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1755-5922.12093","source":{"id":"https://openalex.org/S73613154","display_name":"Cardiovascular Therapeutics","issn_l":"1755-5914","issn":["1755-5914","1755-5922"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2012503689.pdf","grobid_xml":"https://content.openalex.org/works/W2012503689.grobid-xml"},"referenced_works_count":9,"referenced_works":["https://openalex.org/W1989730880","https://openalex.org/W2040612932","https://openalex.org/W2096075279","https://openalex.org/W2101702589","https://openalex.org/W2116404316","https://openalex.org/W2128030263","https://openalex.org/W2148577580","https://openalex.org/W2168483013","https://openalex.org/W2321563682"],"related_works":["https://openalex.org/W1963769231","https://openalex.org/W3009029680","https://openalex.org/W2964822917","https://openalex.org/W2555800785","https://openalex.org/W2708557176","https://openalex.org/W4395109358","https://openalex.org/W2980576252","https://openalex.org/W2900256923","https://openalex.org/W3010349764","https://openalex.org/W4409591611"],"abstract_inverted_index":{"AIMS:":[0],"We":[1],"investigated":[2],"the":[3,10,53,77,169,174,232,249],"relative":[4],"pharmacokinetics,":[5],"pharmacodynamics,":[6],"and":[7,84,113,125,153,192,227],"safety":[8],"of":[9,44,80,86,147,173,214],"proprotein":[11],"convertase":[12],"subtilisin/kexin":[13],"type":[14],"9":[15],"(PCSK9)":[16],"inhibitor":[17],"alirocumab":[18,45,81,215,243],"following":[19,69],"injection":[20,43,100,179,200],"at":[21,156,176],"three":[22,178],"different":[23],"sites.":[24,180],"METHODS:":[25],"Sixty":[26],"healthy":[27],"subjects":[28],"(39":[29],"male,":[30],"21":[31],"female;":[32],"age":[33],"20-45":[34],"years)":[35],"were":[36,61,82,89,97,111,117,184,197,204],"randomized":[37],"to":[38,119],"receive":[39],"a":[40],"single":[41,211],"subcutaneous":[42,212],"75":[46,216],"mg":[47,217],"via":[48,218],"1-mL":[49],"prefilled":[50,219],"pen":[51,220],"into":[52,231],"abdomen,":[54,233,250],"upper":[55,234,251],"arm,":[56,235,252],"or":[57,236,253],"thigh":[58],"(NCT01785329).":[59],"Subjects":[60],"followed":[62],"for":[63,76],"85":[64],"days":[65,68],"\u00b1":[66],"2":[67,198],"study":[70,175],"drug":[71],"administration.":[72],"Pharmacokinetic":[73],"(PK)":[74],"parameters":[75],"systemic":[78],"exposure":[79],"calculated,":[83],"levels":[85,116,133,165],"free":[87,114],"PCSK9":[88,115],"assessed.":[90],"Percentage":[91],"changes":[92],"from":[93],"baseline":[94],"in":[95,129,140,248],"LDL-C":[96,132,164],"compared":[98],"between":[99,122],"site":[101,201],"groups":[102,142],"using":[103],"linear":[104],"mixed-effects":[105],"models.":[106],"RESULTS:":[107],"Alirocumab":[108],"concentration-time":[109],"profiles":[110],"similar,":[112],"reduced":[118],"approximately":[120],"zero":[121],"Day":[123,126,137],"3":[124],"4":[127],"postinjection":[128,139],"all":[130,141,177],"groups.":[131],"reached":[134],"nadir":[135],"on":[136,163],"15":[138],"with":[143,224],"mean":[144],"percentage":[145],"reductions":[146],"48.4%":[148],"(abdomen),":[149,188],"39.5%":[150],"(upper":[151,190],"arm),":[152,191],"45.6%":[154],"(thigh)":[155,194],"this":[157],"time":[158,171],"point.":[159],"A":[160,210],"similar":[161,225],"effect":[162],"was":[166,221],"seen":[167],"across":[168],"entire":[170],"course":[172],"Treatment-emergent":[181],"adverse":[182,207],"events":[183],"experienced":[185],"by":[186],"8/20":[187],"11/20":[189],"13/20":[193],"subjects.":[195],"There":[196,203],"mild/transient":[199],"reactions.":[202],"no":[205],"serious":[206],"events.":[208],"DISCUSSION:":[209],"administration":[213],"well":[222],"tolerated":[223],"pharmacokinetics":[226],"pharmacodynamics":[228],"when":[229],"injected":[230,247],"thigh.":[237,254],"CONCLUSION:":[238],"These":[239],"results":[240],"suggest":[241],"that":[242],"can":[244],"be":[245],"interchangeably":[246]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2012503689","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":7}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
